UK Antibiotic Warning: Co-Amoxiclav Packaging Error Affects All Batches
UK patients taking Sandoz Co-Amoxiclav have been warned about an incorrect dosing table affecting all batches. Find out what patients should know and what action to take.
UK Patients Issued Warning Over Commonly Prescribed Antibiotic
Patients across the UK have been urged to take extra care when using a commonly prescribed antibiotic following the discovery of a packaging error that could potentially lead to an accidental overdose.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety warning concerning Sandoz Co-Amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension. The medicine is widely used to treat various bacterial infections, but an error in its dosing information has raised concerns about patient safety.
According to the safety alert, the incorrect dosing table was included in the product information and could instruct patients or caregivers to administer approximately twice the intended recommended dose.
Importantly, the issue affects all batches of the medicine, meaning patients should not assume that their particular bottle or packaging is unaffected.
What Is the Problem With Co-Amoxiclav?
The issue was reported by pharmaceutical manufacturer Sandoz Limited to the MHRA after an error was identified in the medicine's dosing information.
The affected product is:
- Medicine: Co-Amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension
- Manufacturer: Sandoz Limited
- Problem: Incorrect strength information in the dosing table
- Affected batches: All batches
- Potential risk: Accidental administration of approximately twice the intended recommended dose.
The correct product strength is 250/62.5 mg per 5 ml.
The defective dosing table contained incorrect information that could result in patients receiving a higher quantity of medicine than intended when doses were calculated according to body weight.
This is particularly important for children, as liquid antibiotics are frequently prescribed using weight-based calculations.
What Should Patients Do If They Are Taking This Antibiotic?
The MHRA has advised patients not to use the defective dosing table included in the affected product information.
However, there is an important distinction between the packaging error and the quality of the medicine itself.
Patients have been advised to continue taking their medication as prescribed by their healthcare professional. The safety alert concerns the incorrect dosing information, rather than a problem with the medicine's manufacturing quality.
Anyone currently using this antibiotic should:
- Check the medicine's name and strength against the safety alert.
- Avoid using the defective dosing table to calculate doses.
- Follow the instructions provided by their doctor or pharmacist.
- Contact a pharmacist or prescribing healthcare professional if they are unsure about the correct dose.
- Seek medical attention if they experience symptoms that could indicate an adverse reaction.
Patients should not independently change their prescribed treatment or stop taking antibiotics without seeking appropriate medical advice.
What Are the Possible Side Effects of Taking Too Much Co-Amoxiclav?
Taking more Co-Amoxiclav than recommended may increase the likelihood or severity of certain side effects.
The MHRA has highlighted several possible dose-related adverse reactions, including:
1. Diarrhoea
Diarrhoea is a recognised side effect of Co-Amoxiclav. Taking more than the recommended amount may increase the risk of gastrointestinal problems.
2. Nausea
Some patients may experience nausea, which can become more troublesome following excessive antibiotic exposure.
3. Vomiting
Vomiting is another possible adverse reaction. Persistent vomiting may make it difficult for patients to maintain adequate fluid intake.
4. Abdominal Pain
Patients may experience stomach discomfort, cramps or abdominal pain following excessive doses.
5. Dehydration
Diarrhoea and vomiting can cause significant fluid loss. If these symptoms become severe, dehydration may develop and require medical treatment.
Anyone experiencing concerning symptoms after taking the medicine should seek prompt medical advice. Severe or rapidly worsening symptoms require urgent medical attention.
What Is Co-Amoxiclav Used For?
Co-Amoxiclav is a penicillin-based antibiotic containing two active ingredients: amoxicillin and clavulanic acid.
Amoxicillin works by attacking bacteria and interfering with their ability to build protective cell walls. Clavulanic acid helps prevent certain bacterial enzymes from breaking down amoxicillin, allowing the antibiotic to work against a wider range of bacteria.
Doctors commonly prescribe Co-Amoxiclav to treat bacterial infections, including:
- Ear infections
- Sinus infections
- Skin and soft tissue infections
- Certain respiratory tract infections
- Some dental infections
- Other bacterial infections when clinically appropriate.
The medicine is available in different formulations, including tablets and oral suspensions.
Liquid formulations are particularly useful for children and people who have difficulty swallowing tablets. Their doses may be calculated according to factors such as body weight, age and the type of infection being treated.
This makes accurate dosing information especially important.
What Has the MHRA Said About the Packaging Error?
The MHRA is the UK's medicines regulatory authority. Its responsibilities include monitoring medicine safety, investigating reported problems and issuing warnings when potential risks are identified.
Following notification from Sandoz Limited, the agency confirmed that the defective dosing table could result in approximately twice the intended recommended dose being administered.
The MHRA stated:
"Do not use the Sandoz SmPC for calculating the dosing for weight adjusted administration of this medicine."
The agency also confirmed that the defective Summary of Product Characteristics (SmPC) had been removed from the MHRA products website and the electronic medicines compendium (eMC).
These steps are intended to prevent healthcare professionals and patients from relying on incorrect dosing information.
How Can Patients Report Suspected Side Effects?
Patients and healthcare professionals can report suspected adverse drug reactions through the MHRA Yellow Card scheme.
The scheme allows the regulator to collect information about possible side effects and medicine safety concerns.
Reporting suspected reactions helps the MHRA monitor medicines and identify potential safety issues.
Patients should remember that reporting an adverse reaction does not replace seeking medical attention. Anyone experiencing concerning symptoms should contact a healthcare professional promptly.
Why Accurate Antibiotic Dosing Matters
Antibiotics play an essential role in treating bacterial infections, but taking them correctly is important for patient safety.
Incorrect doses can increase the likelihood of unwanted side effects and may complicate treatment.
Parents and caregivers should take particular care when administering liquid antibiotics to children. Using the correct measuring device and following instructions from a pharmacist or prescriber can help reduce dosing mistakes.
Patients should also avoid relying on outdated online information or packaging instructions that have been specifically identified as defective.
When there is uncertainty about a prescribed dose, a pharmacist or doctor should be consulted before making changes.
Final Thoughts
The latest Co-Amoxiclav safety warning highlights the importance of accurate medicine labelling and reliable dosing information.
Although the MHRA has confirmed that the issue relates to an incorrect dosing table rather than the quality of the antibiotic itself, the potential for accidental overdosing makes the alert important for patients, parents and healthcare professionals.
Anyone using Sandoz Co-Amoxiclav 250/62.5 mg/5 ml oral suspension should avoid relying on the defective dosing table and seek advice from a pharmacist or prescriber if they are uncertain about their medication instructions.
Staying informed, checking official medicine safety updates and following professional medical advice can help reduce avoidable medication risks.
Sources
- The Sun
- Medicines and Healthcare products Regulatory Agency (MHRA): Official UK medicines safety information.
- Electronic Medicines Compendium (eMC): Official medicine information and product details.
Medical Disclaimer
This article is intended for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment recommendations. Patients should consult a qualified doctor or pharmacist regarding medication doses, possible side effects and treatment decisions. Anyone experiencing a suspected serious adverse reaction should seek immediate medical attention. Always refer to official MHRA safety updates for the latest guidance.